Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 2993K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chiodoni, C. Articles by Colombo, M. P. Search for Related Content PubMed PubMed Citation Articles by Chiodoni, C. Articles by Colombo, M. P. Related Collections Related Article Social Bookmarking                            What's this?

¹ Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy
² Ce.S.I., Aging Research Center, G. D'Annunzio University Foundation, 66013 Chieti, Italy
³ Department of Molecular and Cellular Physiology, Louisiana State University Health Science Center, Shreveport, LA 71130

CORRESPONDENCE Mario P. Colombo: mario.colombo{at}istitutotumori.mi.it

Inflammatory cells can either promote or inhibit tumor growth. Here we studied whether CD40, a key molecule for adaptive immune response, has any role in mammary carcinogenesis of BALB/NeuT transgenic tumor-prone mice. We transferred the HER2/neu oncogene into CD40-null background to obtain the CD40-KO/NeuT strain. CD40-KO/NeuT mice showed delayed tumor onset and reduced tumor multiplicity. BM (BM) transplantation experiments excluded a role of BM-derived cells in the reduced tumorigenicity associated with CD40 deficiency. Rather, CD40 expressed by endothelial cells (ECs) takes part to the angiogenic process. Accordingly, large vessels, well organized around the tumor lobular structures, characterize BALB/NeuT tumors, whereas tiny numerous vessels with scarce extracellular matrix are dispersed in the parenchyma of poorly organized CD40-KO/NeuT tumors.

Activated platelets, which may interact with and activate ECs, are a possible source of CD40L. Their localization within tumor vessels prompted the idea of treating BALB/NeuT and CD40-KO/NeuT mice chronically with the anti-platelet drug clopidogrel, known to inhibit platelet CD40L expression. Treatment of BALB/NeuT mice reduced tumor growth to a level similar to CD40-deficient mice, whereas CD40-KO/NeuT mice treated or not showed the same attenuated tumor outgrowth, indicating that activated platelets are the likely source of CD40L in this model. Collectively, these data point to a participation of CD40/CD40L in the angiogenic processes associated with mammary carcinogenesis of BALB/NeuT mice.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

Giving blood: a new role for CD40 in tumorigenesis

Stephan Bergmann and Pier Paolo Pandolfi
J. Exp. Med. 2006 203: 2409-2412. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Teng, M. W. L., Sharkey, J., McLaughlin, N. M., Exley, M. A., Smyth, M. J. (2009). CD1d-Based Combination Therapy Eradicates Established Tumors in Mice. J. Immunol. 183: 1911-1920 [Abstract] [Full Text]  
• Teng, M. W. L., Yue, S., Sharkey, J., Exley, M. A., Smyth, M. J. (2009). CD1d Activation and Blockade: A New Antitumor Strategy. J. Immunol. 182: 3366-3371 [Abstract] [Full Text]  
• Dormond, O., Contreras, A. G., Meijer, E., Datta, D., Flynn, E., Pal, S., Briscoe, D. M. (2008). CD40-Induced Signaling in Human Endothelial Cells Results in mTORC2- and Akt-Dependent Expression of Vascular Endothelial Growth Factor In Vitro and In Vivo. J. Immunol. 181: 8088-8095 [Abstract] [Full Text]  
• Sierra, J. R., Corso, S., Caione, L., Cepero, V., Conrotto, P., Cignetti, A., Piacibello, W., Kumanogoh, A., Kikutani, H., Comoglio, P. M., Tamagnone, L., Giordano, S. (2008). Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. JEM 205: 1673-1685 [Abstract] [Full Text]  
• Serba, S, Schmidt, J, Wentzensen, N, Ryschich, E, Marten, A (2008). Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma. Gut 57: 344-351 [Abstract] [Full Text]  
• Teng, M. W.L., Westwood, J. A., Darcy, P. K., Sharkey, J., Tsuji, M., Franck, R. W., Porcelli, S. A., Besra, G. S., Takeda, K., Yagita, H., Kershaw, M. H., Smyth, M. J. (2007). Combined Natural Killer T-Cell Based Immunotherapy Eradicates Established Tumors in Mice. Cancer Res. 67: 7495-7504 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS